Converting cancer therapies into cures: Lessons from infectious diseases Journal Article
| Authors: | Glickman, M. S.; Sawyers, C. L. |
| Article Title: | Converting cancer therapies into cures: Lessons from infectious diseases |
| Abstract: | During the past decade, cancer drug development has shifted from a focus on cytotoxic chemotherapies to drugs that target specific molecular alterations in tumors. Although these drugs dramatically shrink tumors, the responses are temporary. Research is now focused on overcoming drug resistance, a frequent cause of treatment failure. Here we reflect on analogous challenges faced by researchers in infectious diseases. We compare and contrast the resistance mechanisms arising in cancer and infectious diseases and discuss how approaches for overcoming viral and bacterial infections, such as HIV and tuberculosis, are instructive for developing a more rational approach for cancer therapy. In particular, maximizing the effect of the initial treatment response, which often requires synergistic combination therapy, is foremost among these approaches. A remaining challenge in both fields is identifying drugs that eliminate drug-tolerant "persister" cells (infectious disease) or tumor-initiating/stem cells (cancer) to prevent late relapse and shorten treatment duration. © 2012 Elsevier Inc. |
| Keywords: | treatment response; treatment failure; unclassified drug; review; treatment duration; antineoplastic agents; drug targeting; combined modality therapy; methotrexate; human immunodeficiency virus infection; neoplasm; neoplasms; imatinib; unindexed drug; breast cancer; gene amplification; drug resistance, neoplasm; enzyme inhibitor; dasatinib; chronic myeloid leukemia; mutational analysis; bacteria (microorganisms); cancer therapy; cancer resistance; prostate cancer; leuprorelin; antibiotic resistance; sulfonamide; medical research; cancer stem cell; tamoxifen; cancer relapse; virus infection; feedback system; virus load; bicalutamide; flutamide; gene switching; nilotinib; penicillin derivative; rifampicin; bacterial infection; drug tolerance; tuberculosis; hiv infections; epidermal growth factor receptor kinase inhibitor; zidovudine; lamivudine; serotonin uptake inhibitor; b raf kinase inhibitor; abiraterone; streptomycin; indinavir; cephalosporin derivative; saquinavir; aminoglycoside antibiotic agent; 4 [3 [4 cyano 3 (trifluoromethyl)phenyl] 5,5 dimethyl 4 oxo 2 thioxo 1 imidazolidinyl] 2 fluoro n methylbenzamide; drug resistance, microbial; isoniazid; pyrazinamide; alk kinase inhibitor; chemokine receptor cxcr4 antagonist; platelet derived growth factor receptor kinase inhibitor; drug inactivation |
| Journal Title: | Cell |
| Volume: | 148 |
| Issue: | 6 |
| ISSN: | 0092-8674 |
| Publisher: | Cell Press |
| Date Published: | 2012-03-16 |
| Start Page: | 1089 |
| End Page: | 1098 |
| Language: | English |
| DOI: | 10.1016/j.cell.2012.02.015 |
| PROVIDER: | scopus |
| PUBMED: | 22424221 |
| PMCID: | PMC3465702 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 April 2012" - "CODEN: CELLB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work